华西虚拟期刊

华西虚拟期刊

查看全文

Deferoxamine (DFO), an iron chelator, is commonly used to remove excess iron from the body. DFO has also been demonstrated to have anti-tumor effect. However, there is no available report on the effect of deferoxamine on mesenchymal stromal cells (MSCs). In this study, we first isolated tumor-associated MSCs (TAMSCs) from EG-7 tumors, which were positive for CD29, CD44, CD73, CD90 and CD105. Ex vivo cultured stem cells derived from tumor and bone marrow compartment were exposed to DFO. We demonstrated that DFO had growth-arresting and apoptosis-inducing effect on TAMSCs and bone marrow MSCs (BMMSCs). DFO also influenced the expression pattern of adhesion molecule VCAM-1 on both TAMSCs and BMMSCs. Notwithstanding its widespread use, our results here warrants caution in the application of DFO, and also highlights the need for careful evaluation of the bone marrow compartment in patients receiving DFO treatment. (C) 2016 Elsevier B.V. All rights reserved.

Key words: IRON CHELATION; STEM-CELLS; OVARIAN-CARCINOMA; DIABETIC-RATS; DESFERRIOXAMINE; ICAM-1; APOPTOSIS; TOXICITY; SURVIVAL; THERAPY

引用本文: . . 华西虚拟期刊, 2000, 1(1): 58-64-. doi: 10.1016/j.etap.2016.11.014 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,